针刺治疗卵巢储备功能减退获益人群血清microRNA表达特征研究

注册号:

Registration number:

ITMCTR2025000004

最近更新日期:

Date of Last Refreshed on:

2025-01-03

注册时间:

Date of Registration:

2025-01-03

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗卵巢储备功能减退获益人群血清microRNA表达特征研究

Public title:

Characteristics of serum microRNA expression in patients who benefit from acupuncture treatment of diminished ovarian reserve

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗卵巢储备功能减退获益人群血清microRNA表达特征研究

Scientific title:

Characteristics of serum microRNA expression in patients who benefit from acupuncture treatment of diminished ovarian reserve

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪小滟

研究负责人:

许焕芳

Applicant:

Xiaoyan Wang

Study leader:

Huanfang Xu

申请注册联系人电话:

Applicant telephone:

15282277253

研究负责人电话:

Study leader's telephone:

15711082019

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xiaoyan015@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

huanfang_xu@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国北京市东城区东直门内南小街16号

研究负责人通讯地址:

中国北京市东城区东直门内南小街16号

Applicant address:

16 Nanxiao Street Dongzhimennei Dongcheng District Beijing China

Study leader's address:

16 Nanxiao Street Dongzhimennei Dongcheng District Beijing China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院针灸研究所

Applicant's institution:

Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

中国中医科学院西苑医院医学伦理委员会2024XLW004-2

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中国中医科学院西苑医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Xiyuan Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2024/12/2 0:00:00

伦理委员会联系人:

贾敏

Contact Name of the ethic committee:

Min Jia

伦理委员会联系地址:

中国北京市海淀区西苑操场1号

Contact Address of the ethic committee:

No. 1 Xiyuan Playground Haidian District Beijing China

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-62835646

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xiyuanlunli@163.com

研究实施负责(组长)单位:

中国中医科学院针灸研究所

Primary sponsor:

Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

中国北京市东城区东直门内南小街16号

Primary sponsor's address:

16 Nanxiao Street Dongzhimennei Dongcheng District Beijing China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

北京市

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

中国中医科学院针灸研究所

具体地址:

中国北京市东城区东直门内南小街16号

Institution
hospital:

Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences

Address:

No. 16 Nnan Street Dongzhimen Dongcheng District Beijing China

经费或物资来源:

首都卫生发展科研专项项目

Source(s) of funding:

Capital Health Development and Scientific Research Special Project

研究疾病:

卵巢储备功能减退

研究疾病代码:

Target disease:

Diminished ovarian reserve

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

巢式病例-对照研究

Nested case-control study

研究所处阶段:

Study phase:

其它

Others

研究目的:

明确DOR针刺获益人群血清miRNA的表达特征,为DOR针刺获益人群的精准选择提供依据。

Objectives of Study:

To clarify the expression characteristics of serum miRNAs in the beneficiary population of patients with decreased ovarian reserve in acupuncture treatment so as to provide a basis for the accurate selection of the beneficiary population of DOR acupuncture.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合DOR的诊断标准; (2)女性,22岁≤年龄<40岁; (3)自愿参加试验,并且签署知情同意书。

Inclusion criteria

(1) Meet the diagnostic criteria of DOR; (2) Female 22 years old≤ age < 40 years old; (3) Voluntarily participate in the trial and sign the informed consent form.

排除标准:

(1)FSH≥25 IU/L; (2)多囊卵巢综合征、未经控制的高催乳素血症、甲状腺功能减退等影响排卵的疾病; (3)医源性因素(如盆腔手术、放化疗、子宫动脉栓塞、药物如激素、免疫抑制剂等)引起的POA; (4)染色体核型异常; (5)合并严重心脑血管、肝、肾、恶性肿瘤、造血系统及精神疾病者。

Exclusion criteria:

(1)FSH≥25 IU/L (2) Polycystic ovary syndrome uncontrolled hyperprolactinemia hypothyroidism and other diseases that affect ovulation; (3) POA caused by iatrogenic factors (such as pelvic surgery chemoradiotherapy uterine artery embolization drugs such as hormones immunosuppressants etc.); (4) karyotypic abnormalities; (5) Patients with severe cardiovascular and cerebrovascular hepatic kidney malignant tumors hematopoietic system and mental diseases.

研究实施时间:

Study execute time:

From 2024-12-02

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-01-07

To      2026-09-30

干预措施:

Interventions:

组别:

针刺组中有效病例

样本量:

20

Group:

Effective cases in the acupuncture group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

Acupuncture

Intervention code:

组别:

针刺组中无效病例

样本量:

20

Group:

Ineffective cases in the acupuncture group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

Acupuncture

Intervention code:

组别:

针刺组

样本量:

90

Group:

Acupuncture group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

Acupuncture

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

东城区

Country:

China

Province:

Beijing

City:

Dongcheng District

单位(医院):

中国中医科学院针灸医院

单位级别:

其他

Institution/hospital:

Acupuncture Hospital of China Academy of Chinese Medical Sciences

Level of the institution:

Other

测量指标:

Outcomes:

指标中文名:

窦卵泡数

指标类型:

主要指标

Outcome:

Antral Follicle Counting

Type:

Primary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

指标中文名:

促卵泡生成素

指标类型:

次要指标

Outcome:

Follicle Stimulating Hormone

Type:

Secondary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

指标中文名:

抗缪勒管激素

指标类型:

次要指标

Outcome:

anti-Müllerian hormone

Type:

Secondary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

指标中文名:

获卵数

指标类型:

次要指标

Outcome:

Number of eggs retrieved

Type:

Secondary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

指标中文名:

临床妊娠率

指标类型:

次要指标

Outcome:

Clinical pregnancy rate

Type:

Secondary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

指标中文名:

血清miRNA

指标类型:

主要指标

Outcome:

microRNA

Type:

Primary indicator

测量时间点:

第0周,第12周

测量方法:

高通量测序

Measure time point of outcome:

Measure method:

指标中文名:

促黄体生成素

指标类型:

次要指标

Outcome:

Luteinizing Hormone

Type:

Secondary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

指标中文名:

雌二醇

指标类型:

次要指标

Outcome:

Estradiol

Type:

Secondary indicator

测量时间点:

第0周,第12周

测量方法:

Measure time point of outcome:

Weeks 0,12

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 22
Min age years
最大 40
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用网络平台公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

use web-based public database

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统